Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
MMP2 Biologics Sequence Review Report 2026: 72 kDa type IV collagenase Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MMP1 Biologics Sequence Review Report 2026: Interstitial collagenase Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MMP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MME Biologics Sequence Review Report 2026: Neprilysin Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MME sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MC2R Biologics Sequence Review Report 2026: Adrenocorticotropic hormone receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MC2R sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
MADCAM1 Biologics Sequence Review Report 2026: Mucosal addressin cell adhesion molecule 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MADCAM1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
LRIG3 Biologics Sequence Review Report 2026: Leucine-rich repeats and immunoglobulin-like domains protein 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LRIG3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
LRIG2 Biologics Sequence Review Report 2026: Leucine-rich repeats and immunoglobulin-like domains protein 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LRIG2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
LRIG1 Biologics Sequence Review Report 2026: Leucine-rich repeats and immunoglobulin-like domains protein 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LRIG1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
LAMP3 Biologics Sequence Review Report 2026: Lysosome-associated membrane glycoprotein 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LAMP3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
LAMP2 Biologics Sequence Review Report 2026: Lysosome-associated membrane glycoprotein 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LAMP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
LAMP1 Biologics Sequence Review Report 2026: Lysosome-associated membrane glycoprotein 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LAMP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
KLRC4 Biologics Sequence Review Report 2026: NKG2-F type II integral membrane protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of KLRC4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.